Washington Business Journal

March 25, 2015 3:25 PM

5 0

Rockville-based Emergent BioSolutions, whose anthrax vaccine BioThrax is driving revenue growth, will move toward final clinical trials for its next generation anthrax vaccine with a $31 million BARDA contract.

Gaithersburg-based Emergent BioSolutions Inc. is adding a $31 million contract from the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority to its ongoing work developing a next-generation anthrax vaccine.

Also watch: The 1-11 49ers just handed a guy with 64 career catches a $35 million extension

Read more

To category page